小剂量阿糖胞苷联合沙利度胺治疗骨髓增生异常综合征疗效观察  

Therapeutic effect of low-dose cytarabine combined with thalidomide on myelodysplastic syndrome

作　　者：刘静[1] 李云[1] 王晶[1] 石春平[1] LIU Jing;LI Yun;WANG Jing;SHI Chunping(Department of Hematology,Daqing Oilfield General Hospital,Daqing 163001,China)

机构地区：[1]大庆油田总医院血液科

出　　处：《中国现代医生》2019年第24期110-112,共3页China Modern Doctor

摘　　要：目的探讨小剂量阿糖胞苷联合沙利度胺治疗骨髓增生异常综合征的疗效。方法选取2016年1月~2018年1月在我院就诊的骨髓增生异常综合征患者60例,随机分为两组,每组30例,两组均予雄激素、促红细胞生成素、输血等治疗6个月。观察组予小剂量阿糖胞苷联合沙利度胺治疗。治疗后对其临床疗效、不良反应及血象各项观察指标进行对比分析。结果观察组患者治疗后的总有效率达80.00%,显著高于对照组(P<0.05)。观察组患者治疗后Hb、Plt、WBC水平分别为[(89.12±16.85)g/L]、[(90.56±13.90)×10^9/L]、[(5.46±1.31)×10^9/L],分别显著高于对照组患者治疗后的Hb、Plt、WBC水平[(73.12±11.37)g/L、(85.61±12.05)×10^9/L、(4.13±0.41)×10^9/L)],两组比较,差异具有显著性(P<0.05)。两组治疗后不良反应发生率比较,差异无统计学意义(P>0.05)。结论小剂量阿糖胞苷联合沙利度胺治疗骨髓增生异常综合征疗效确切,可以显著改善患者的血象,安全性好,无明显不良反应,改善患者的临床症状,值得临床广泛推广和应用。Objective To investigate the efficacy of low-dose cytarabine combined with thalidomide in the treatment of myelodysplastic syndrome.Methods Sixty patients with myelodysplastic syndrome who were treated in our hospital from January 2016 to January 2018 were randomly divided into two groups,with 30 cases in each group.Both groups were treated with androgen,erythropoietin,blood transfusion for 6 months.The observation group was treated with low dose cytarabine combined with thalidomide.After treatment,the clinical efficacy,adverse reactions and blood routine indicators were compared and analyzed.Results The total effective rate of the observation group was 80.00%after treatment,which was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).The levels of Hb,Plt and WBC in the observation group after treatment were(89.12±16.85)g/L,(90.56±13.90)×10^9/L and(5.46±1.31)×10^9/L,respectively,which were significantly higher than the levels of Hb,Plt and WBC[(73.12±11.37)g/L,(85.61±12.05)×10^9/L,(4.13±0.41)×10^9/L]in the control group.There were significant differences between the two groups(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group after treatment(P>0.05).Conclusion Low-dose cytarabine combined with thalidomide is effective in the treatment of myelodysplastic syndrome.It can significantly improve the blood routine of patients,has good safety,has no obvious adverse reactions,and improve the clinical symptoms of patients.It is worthy of widespread clinical application and application.

关 键 词：骨髓增生异常综合征 阿糖胞苷 沙利度胺 不良反应 

分 类 号：R551.3[医药卫生—血液循环系统疾病]